CHICAGO, IL / ACCESSWIRE / June 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S....
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key...
TEL AVIV, Israel, June 17, 2024 /PRNewswire/ -- Briya, a leading medical data retrieval network, proudly announces the appointment of...
A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s...
The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was deliveredBRAINTREE,...
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71%...
The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into...
Vivalink's survey reveals strong consumer support for flexible care models, indicating a need for home based care as part of...
CHICAGO, IL / ACCESSWIRE / June 13, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to...
Led by Ecliptic Capital with strategic investment from Memorial Hermann Health System, AARP and the Texas Medical Center Venture Fund...
- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of...
SHANGHAI, June 11, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading...
PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative...
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 12, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the...
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce...
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT...
– Approval by Health Canada regulatory authority immediately clears the way for Pure Impact™ with PlyoPulse™ device launch and commercialization in...